Reanalysis of Clinical Trial Data Confirms LipiGesic® M has Robust Efficacy for Treatment of Migraine Headache and Associated Symptoms

PuraMed BioScience^®, Inc., (PMBS: OTCBB) announces that the reanalysis of the clinical trial results of its homeopathic formulation, LipiGesic^® M, found that the migraine medication has “robust efficacy.” These results were  featured in the February 2013 issue of Headache: The Journal of Head and Face Pain, the official journal of the American Headache Society^®.

The article, Sublingual Feverfew/Ginger (LipiGesic M) Reanalysis of Data (attributed to Roger Cady, MD; Richard Lipton, MD; Daniel Serrano, PhD; and Rebecca Browning, BS) quoted Dr. Serrano, who provided the reanalysis as saying, “In conclusion, irrespective of design-type employed, the efficacy of sublingual feverfew/ginger (LipiGesic M) appears robust…”

The original double-blind, placebo-controlled clinical trial for LipiGesic M, completed in 2010 and published in the July 2011 issue of Headache: The Journal of Head and Face Pain, concluded that 64 percent of patients who used LipiGesic M found relief.

“This reanalysis not only confirms LipiGesic M is a highly effective, over-the-counter medication for the treatment of acute migraine pain,” said Russell Mitchell, chairman and CEO of PuraMed BioScience. “It also shows that if our study had included a larger patient population, LipiGesic M would have demonstrated a stronger efficacy across all measurement points.”

In a preceding article published in Drugs in 2012, Ryan Cady, Candace Shade, and Roger Cady, MD, describe LipiGesic M as an “excellent first-line therapy.” The article “Advances in Drug Development for Acute Migraine” goes on to cite LipiGesic M’s lower cost, its OTC availability, its unlikelihood to cause rebound headache, and its compatibility with other treatment options as advantages in acute migraine treatment.

“We have provided a safe, highly effective, OTC solution to migraine pain that performs as well as, if not better than prescription medications without the high cost, drowsiness, or the need for a doctor’s visit,” said Mitchell. “We are looking forward to the findings of the children’s study that was recently concluded to compare results across all age groups.”

LipiGesic^®M is distributed nationally in Walgreens and CVS/pharmacy stores.

Related posts:

1. LipiGesic™ M is Recognized by Headache Experts as an Excellent First-Line Therapy for Acute Migraine Treatment
2. Video Release — Top-Tier Medical Journal Headache Publishes Clinical Study Results of PuraMed BioScience, Inc. Revolutionary New Migraine Medication LipiGesic® M
3. Top-Tier Medical Journal Headache Publishes in Print the Clinical Study Results of PuraMed BioScience, Inc. Revolutionary New Migraine Medication LipiGesic® M
4. A Double-Blind Placebo-Controlled Pilot Study of Sublingual Feverfew and Ginger (LipiGesic® M) in the Treatment of Migraine
5. A Double-Blind Placebo-Controlled Pilot Study of Sublingual Feverfew and Ginger (LipiGesic® M) in the Treatment of Migraine